Allogene Therapeutics, Inc. (ALLO)
1.325
0.00 (0.00%)
USD |
NASDAQ |
Oct 21, 16:00
1.325
0.00 (0.00%)
After-Hours: 20:00
Allogene Therapeutics Enterprise Value : 205.71M for Oct. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 20, 2026 | 205.71M |
| October 19, 2026 | 195.35M |
| October 16, 2026 | 198.81M |
| October 15, 2026 | 209.17M |
| October 14, 2026 | 195.35M |
| October 13, 2026 | 191.90M |
| October 12, 2026 | 229.89M |
| October 09, 2026 | 250.61M |
| October 08, 2026 | 229.89M |
| October 07, 2026 | 240.25M |
| October 06, 2026 | 250.61M |
| October 05, 2026 | 264.42M |
| October 02, 2026 | 264.42M |
| October 01, 2026 | 278.24M |
| September 30, 2026 | 298.96M |
| September 29, 2026 | 305.86M |
| September 28, 2026 | 309.32M |
| September 25, 2026 | 316.22M |
| September 24, 2026 | 323.13M |
| September 23, 2026 | 323.13M |
| September 22, 2026 | 336.95M |
| September 21, 2026 | 330.04M |
| September 18, 2026 | 330.04M |
| September 17, 2026 | 343.85M |
| September 16, 2026 | 330.04M |
| Date | Value |
|---|---|
| September 15, 2026 | 340.40M |
| September 14, 2026 | 361.12M |
| September 11, 2026 | 361.12M |
| September 10, 2026 | 354.21M |
| September 09, 2026 | 343.85M |
| September 08, 2026 | 388.75M |
| September 04, 2026 | 426.74M |
| September 03, 2026 | 430.19M |
| September 02, 2026 | 430.19M |
| September 01, 2026 | 431.92M |
| August 31, 2026 | 437.10M |
| August 28, 2026 | 444.00M |
| August 27, 2026 | 468.18M |
| August 26, 2026 | 450.91M |
| August 25, 2026 | 495.80M |
| August 24, 2026 | 447.46M |
| August 21, 2026 | 468.18M |
| August 20, 2026 | 471.63M |
| August 19, 2026 | 516.53M |
| August 18, 2026 | 447.46M |
| August 17, 2026 | 464.72M |
| August 14, 2026 | 454.36M |
| August 13, 2026 | 430.19M |
| August 12, 2026 | 461.27M |
| August 11, 2026 | 478.54M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.090B |
| Oncolytics Biotech, Inc. | 58.48M |
| Sangamo Therapeutics, Inc. | 37.32M |
| Sarepta Therapeutics, Inc. | 2.282B |
| Anixa Biosciences, Inc. | 77.73M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -42.68M |
| Revenue (Quarterly) | 4.64M |
| Total Expenses (Quarterly) | 47.32M |
| EPS Diluted (Quarterly) | -0.1297 |
| Gross Profit Margin (Quarterly) | 43.00% |
| Profit Margin (Quarterly) | -919.8% |
| Earnings Yield | -50.20% |
| Normalized Earnings Yield | -50.20 |